Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
The rising prevalence of type 2 diabetes and obesity, increasing adoption for chronic weight management among non-diabetic populations, expansion of pharmaceutical R&D pipelines, and growing demand in emerging markets with high metabolic disease burden are key drivers of market growth
Other GLP-1 receptor agonists have also been shown to be effective at treating both type 2 diabetes and obesity in children, leading to significant reductions in blood sugar levels, body weight, body mass index (BMI), and blood pressure
Nausea, constipation, diarrhea, bloating, and reduced appetite are frequently reported, especially during dose increases
If more than 4 days have passed, skip the missed dose and resume the next scheduled dose
US$ 25.95
US$ 24.16
US$ 27.53
US$ 29.22
US$ 23.55
US$ 26.46
US$ 24.98
US$ 21.91
US$ 27.41
